Sponsor Dossier
Clinect
Sponsor Dossier for Clinect. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: CATAPRES
- Brand: FELODUR ER
- Brand: FLUORESCEIN
- Brand: HALDOL
- Brand: IBAVYR
- Brand: IMDUR
- Brand: IOPIDINE
- Brand: LARGACTIL
- Device (sponsor): Needle, subcutaneous injection/infusion port
- Device (sponsor): Infusion administration set, infusion pump
About
Clinect is an Australian Private Company with ABN 76 150 558 473, based in Victoria and currently active.
Portfolio
Clinect has 21 brands on the ARTG, with all 21 cleared for indexing. All 21 brands have Product Information on file. Ten brands are PBS-listed, two have PBAC outcomes on record, and one has an AusPAR on record.
Therapeutic focus
— Cardiology: 7 brands — Neurology: 4 brands — Ophthalmology: 3 brands — Psychiatry: 2 brands — Oncology: 2 brands — Infectious Disease: 1 brand — Rare Disease: 1 brand — Endocrinology: 1 brand
PBS footprint
Clinect has ten brands with at least one PBS-listed item, with the latest PBS schedule date their portfolio touched being 1 May 2026.
Regulatory activity
Clinect's latest PBAC outcome is dated 1 November 2022, with two brands holding PBAC outcomes on record. The latest AusPAR is dated 21 February 2024, with one brand holding an AusPAR on record.